Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Solvay Mulls Options For Drug Business

by Michael McCoy
April 6, 2009 | A version of this story appeared in Volume 87, Issue 14

Solvay is holding discussions with third parties as it analyzes options for its pharmaceutical business. The business had sales last year of almost $3.6 billion, about 28% of Solvay's total sales. After AkzoNobel's 2007 sale of its drug business to Schering-Plough, Solvay is one of the last big European companies with businesses that span pharmaceuticals, chemicals, and plastics.

Article:

This article has been sent to the following recipient:

1 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.